Supplementary Documents [IFRS]

Financial results for the fiscal year 2017 (FY2017)

Astellas Pharma Inc.

- FY2017 Financial Results
  - For the year ended March 31, 2018
  - Three months ended March 31, 2018
- Pipeline list

Cautionary Notes
In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[For the year ended March 31,2018]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY16 Full Year	FY17 Full Year	Change	Change (%)	FY17 Revised Forecasts	FY18 Full Year	Change from FY17 (%)
Sales	1,311.7	1,300.3	-11.3	-0.9%	1,297.0	1,278.0	-1.7%
Cost of sales	320.5	294.2	-26.3	-8.2%			
Ratio to Sales	24.4%	22.6%					
Gross profit	991.2	1,006.1	14.9	1.5%			
SG&A expenses	470.8	478.3	7.6	1.6%			
Ratio to Sales	35.9%	36.8%					
Advertising and Sales Promotion	144.1	152.1	8.0	5.6%			
Personnel expenses	177.0	178.5	1.5	0.8%			
Other	149.7	147.7	-2.0	-1.3%			
R&D expenses	208.1	220.8	12.7	6.1%	218.0	214.0	-3.1%
Ratio to Sales	15.9%	17.0%			16.8%	16.7%	
Amortisation of intangible assets	35.8	35.8	0.0	0.0%			
Share of profits/losses of associates and joint ventures	-1.9	-2.4	-0.6	-			
Other income	9.6	11.9	2.3	23.7%			
Fair value remeasurements on contingent consideration	-	1.2	1.2	-			
Gain from remeasurement relating to business combinations	-	5.9	5.9	-			
Other expense	23.3	67.3	44.0	188.7%			
Impairment losses	18.1	42.4	24.3	134.7%			
Restructuring costs	3.1	9.2	6.0	193.6%			
Net foreign exchange losses	-	10.5	10.5	-			
Fair value remeasurements on contingent consideration	-	1.2	1.2	-			
Operating profit	260.8	213.3	-47.6	-18.2%	222.0	265.0	24.3%
Ratio to Sales	19.9%	16.4%			17.1%	20.7%	
Finance income	22.9	6.6	-16.3	-71.0%			
Gain on sales of available-for-sale financial assets	21.3	4.7	-16.5	-77.7%			
Finance expense	2.0	1.8	-0.2	-9.8%			
Impairment losses for available-for-sale financial assets	0.6	0.5	-0.2	-26.2%			
Profit before tax	281.8	218.1	-63.7	-22.6%	228.0	266.0	22.0%
Ratio to Sales	21.5%	16.8%			17.6%	20.8%	
Income tax expense	63.1	53.4	-9.6	-15.3%			
Profit for the year	218.7	164.7	-54.0	-24.7%	180.0	213.0	29.3%
Ratio to Sales	16.7%	12.7%			13.9%	16.7%	
Comprehensive income	174.6	198.5	23.9	13.7%			

2. Consolidated Results (Core Basis)

Unit: B¥

	FY16 Full Year	FY17 Full Year	Change	Change (%)	Unit: B¥ FY17 Revised Forecasts	Forecasts FY18 Full Year	Change from FY17 Change (%)
Sales	1,311.7	1,300.3	-11.3	-0.9%	1,297.0	1,278.0	-1.7%
Cost of sales	320.5	294.2	-26.3	-8.2%			
Ratio to Sales	24.4%	22.6%					
Gross profit	991.2	1,006.1	14.9	1.5%			
SG&A expenses	470.8	478.3	7.6	1.6%			
Ratio to Sales	35.9%	36.8%					
Advertising and Sales Promotion	144.1	152.1	8.0	5.6%			
Personnel expenses	177.0	178.5	1.5	0.8%			
Other	149.7	147.7	-2.0	-1.3%			
R&D expenses	208.1	220.8	12.7	6.1%	218.0	214.0	-3.1%
Ratio to Sales	15.9%	17.0%			16.8%	16.7%	
Amortisation of intangible assets	35.8	35.8	0.0	0.0%			
Share of profits/losses of associates and joint ventures	-1.9	-2.4	-0.6	-			
Operating profit	274.6	268.7	-5.9	-2.1%	258.0	262.0	-2.5%
Ratio to Sales	20.9%	20.7%			19.9%	20.5%	
Finance income	1.7	1.9	0.2	14.5%			
Finance expense	1.3	1.2	-0.1	-8.1%			
Profit before Tax	274.9	269.4	-5.5	-2.0%			
Ratio to Sales	21.0%	20.7%					
Income tax expense	61.6	65.1	3.5	5.7%			
Profit for the year	213.3	204.3	-9.0	-4.2%	201.0	210.0	2.8%
Ratio to Sales	16.3%	15.7%			15.5%	16.4%	

3. Exchange Rate

Unit: yen

	FY16 Ave.	FY17 Ave.	FY16 End	FY17 End	Unit: yen FY17 Revised Forecasts	Forecasts FY18 Full Year
USD/Yen	108	111	112	106	111	105
EUR/Yen	119	130	120	131	128	130

* Exchange rate fluctuations had positive impact by 43.3 billion yen on sales and positive impact by 13.1 billion yen on Core operating profit in FY2017

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY16			FY17		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**1,311.7**	**-**	**1,311.7**	**1,300.3**	**-**	**1,300.3**
Cost of sales	320.5	-	320.5	294.2	-	294.2
Gross profit	**991.2**	**-**	**991.2**	**1,006.1**	**-**	**1,006.1**
SG&A expenses	470.8	-	470.8	478.3	-	478.3
R&D expenses	208.1	-	208.1	220.8	-	220.8
Amortisation of intangible assets	35.8	-	35.8	35.8	-	35.8
Share of losses of associates and joint ventures	-1.9	-	-1.9	-2.4	-	-2.4
Other income *1	9.6	-9.6	-	11.9	-11.9	-
Other expense *1	23.3	-23.3	-	67.3	-67.3	-
Operating profit	**260.8**	**13.7**	**274.6**	**213.3**	**55.4**	**268.7**
Finance income *2	22.9	-21.3	1.7	6.6	-4.7	1.9
Finance expense *2	2.0	-0.7	1.3	1.8	-0.6	1.2
Profit before tax	**281.8**	**-6.9**	**274.9**	**218.1**	**51.3**	**269.4**
Income tax expense	63.1	-1.5	61.6	53.4	11.6	65.1
Profit for the year	**218.7**	**-5.4**	**213.3**	**164.7**	**39.6**	**204.3**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses, loss on the restructuring, litigation costs and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

5. Sales by Region

Unit: B¥

		FY16 Full Year	FY17 Full Year	Change	Change (%)	FY17 Revised Forecasts	FY18 Full Year	Change from FY17 (%)
Sales		1,311.7	1,300.3	-11.3	-0.9%	1,297.0	1,278.0	-1.7%
	Japan	480.8	421.2	-59.6	-12.4%	423.0	396.8	-5.8%
	Ratio to Sales	36.7%	32.4%			32.6%	31.0%	
	Americas	412.4	433.3	20.9	5.1%	432.9	424.4	-2.1%
	Ratio to Sales	31.4%	33.3%			33.4%	33.2%	
	EMEA	330.8	343.8	13.0	3.9%	339.7	343.9	0.0%
	Ratio to Sales	25.2%	26.4%			26.2%	26.9%	
	Asia and Oceania	87.7	102.0	14.3	16.3%	101.4	112.9	10.7%
	Ratio to Sales	6.7%	7.8%			7.8%	8.8%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

6. Per Share Information

	FY16 Full Year	FY17 Full Year	FY17 Revised Forecasts	FY18 Full Year
The number of shares issued (thousand)	2,153,823	2,068,823		
Treasury Shares (thousand)	88,817	92,670		
The number of shares issued after deducting Treasury Shares (thousand)	2,065,005	1,976,152		
Earnings per share (yen)	103.69	81.11	88.15	107.79
Earnings per share (yen) core base	101.15	100.64	98.43	106.27
Dividend per share (yen)	34	36	36	38
Return on Equity (%)	17.3%	13.0%		
Dividend on Earnings (%)	5.6%	5.7%		

7. Addition to Property,Plant and Equipment, Depreciation/Amortisation

Unit: B¥

		FY16 Full Year	FY17 Full Year	Change	Change (%)	FY17 Revised Forecasts	FY18 Full Year	Change from FY17 (%)
Addition to Property, Plant and Equipment								
	Consolidated	23.9	24.1	0.2	0.9%	25.0	27.0	12.0%
Depreciation (PP&E)								
	Consolidated	21.9	22.0	0.2	0.8%	23.0	22.0	-0.2%
Amortisation (Intangible Assets) *								
	Consolidated	41.9	42.8	0.9	2.2%	42.0	40.0	-6.6%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

8. Sales of major products

1) Sales of global products

Unit: B¥

	FY16 Full Year	FY17 Full Year	Change	Change (%)	FY17 Revised Forecasts	FY18 Full Year	Change from FY17 (%)
XTANDI	252.1	294.3	42.2	16.8%	291.3	310.3	5.5%
US	131.7	144.4	12.7	9.7%	140.4	142.3	-1.4%
ex-US	120.4	149.9	29.5	24.5%	151.0	168.1	12.1%
Japan	23.4	26.1	2.7	11.4%	25.9	28.2	8.2%
Americas (ex-US)	7.7	11.3	3.5	45.7%	11.0	12.4	10.5%
EMEA	85.3	106.7	21.4	25.1%	108.4	119.7	12.2%
Asia and Oceania	4.0	5.8	1.9	47.3%	5.6	7.7	31.0%
Eligard	15.9	16.5	0.6	3.8%	18.3	17.0	2.9%
EMEA	15.7	16.1	0.5	3.0%	17.8	16.4	1.7%
Asia and Oceania	0.2	0.4	0.1	55.9%	0.5	0.6	56.1%
Vesicare	116.1	102.3	-13.8	-11.9%	106.2	96.9	-5.2%
Japan	25.6	23.9	-1.7	-6.8%	24.0	22.7	-4.8%
Americas	53.1	41.3	-11.8	-22.3%	45.5	39.5	-4.1%
EMEA	32.0	31.7	-0.4	-1.2%	31.0	29.7	-6.0%
Asia and Oceania	5.0	5.0	0.0	0.4%	5.2	4.5	-11.2%
Betanis/Myrbetriq/BETMIGA	98.8	125.7	26.9	27.2%	126.1	146.2	16.3%
Japan	25.9	29.5	3.6	13.7%	29.6	32.0	8.8%
Americas	55.3	72.8	17.5	31.7%	72.8	84.7	16.3%
EMEA	14.1	18.3	4.1	29.4%	18.3	22.0	20.4%
Asia and Oceania	3.5	5.2	1.7	47.7%	5.4	7.5	43.0%
Harnal/Omnic	47.7	49.6	2.0	4.1%	50.8	46.9	-5.4%
Sales by Astellas	45.4	47.5	2.1	4.6%	48.9	45.8	-3.5%
Japan	9.2	7.4	-1.7	-19.0%	7.4	5.1	-31.7%
EMEA	14.1	15.7	1.7	11.9%	16.1	15.8	0.1%
Asia and Oceania	21.1	23.2	2.1	10.1%	24.2	23.8	2.4%
Bulk and Royalties	2.3	2.2	-0.1	-5.8%	1.9	1.1	-47.0%
Prograf	186.2	198.5	12.3	6.6%	194.8	190.7	-3.9%
Sales by Astellas	183.5	195.2	11.6	6.3%	191.8	188.9	-3.2%
Japan (Including Graceptor)	48.8	48.3	-0.6	-1.1%	48.8	46.3	-4.1%
Americas	27.3	25.7	-1.6	-5.9%	25.5	20.1	-21.8%
EMEA	70.1	78.7	8.6	12.2%	77.2	76.0	-3.4%
Advagraf	30.0	35.3	5.4	17.9%			
Asia and Oceania	37.3	42.5	5.2	14.0%	40.3	46.5	9.3%
Exports to third parties	2.6	3.3	0.7	25.4%	3.0	1.8	-46.2%
Funguard/MYCAMINE	40.3	41.0	0.7	1.9%	40.3	34.8	-15.2%
Japan	11.2	10.6	-0.6	-5.7%	11.0	7.8	-26.3%
Americas	12.2	12.3	0.1	0.8%	11.3	9.9	-19.5%
EMEA	10.8	11.6	0.8	7.6%	11.0	9.1	-21.5%
Asia and Oceania	6.0	6.4	0.5	7.7%	7.0	7.9	22.9%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

<Global products>	FY16 Full Year	FY17 Full Year	Change	Change (%)	Unit: B¥ FY17 Revised Forecasts	Forecasts FY18 Full Year	Change from FY17 Change (%)
XTANDI	23.4	26.1	2.7	11.4%	25.9	28.2	8.2%
Vesicare	25.6	23.9	-1.7	-6.8%	24.0	22.7	-4.8%
Betanis	25.9	29.5	3.6	13.7%	29.6	32.0	8.8%
Harnal	9.2	7.4	-1.7	-19.0%	7.4	5.1	-31.7%
Prograf （Including Graceptor ）	48.8	48.3	-0.6	-1.1%	48.8	46.3	-4.1%
Funguard	11.2	10.6	-0.6	-5.7%	11.0	7.8	-26.3%
<Local products in Japan>							
Micardis [Family]	93.2	46.3	-46.9	-50.3%	49.4	17.7	-61.7%
Micombi	9.4	4.9	-4.5	-47.8%			
Micamlo	26.2	13.8	-12.4	-47.5%			
Celecox	47.6	48.3	0.8	1.6%	48.2	49.4	2.1%
Symbicort	39.3	39.5	0.2	0.6%	39.8		
Bonoteo	13.8	13.3	-0.5	-3.6%	13.2	10.4	-21.7%
Geninax	10.1	9.2	-1.0	-9.4%	10.0	8.7	-5.2%
Vaccines	34.5	29.4	-5.1	-14.9%	30.5	36.8	25.4%
Argamate	5.8	5.8	-0.1	-1.0%	5.8	5.3	-7.5%
Gonax	4.5	4.7	0.2	3.9%	4.8	5.1	9.2%
Cimzia	7.7	9.0	1.2	16.2%	8.8	9.8	8.8%
Suglat	9.5	11.6	2.1	22.5%	11.7	13.3	13.9%
Repatha		1.6					
Linzess		1.4				9.2	562.7%
Lipitor	23.2	19.6	-3.6	-15.3%	19.7	15.3	-21.9%
Myslee	14.7	13.3	-1.4	-9.5%	13.2	10.9	-18.1%
Seroquel	7.5	6.2	-1.3	-17.7%	6.1	4.5	-27.6%
Total Rx Sales In Japanese market	452.7	383.4	-69.4	-15.3%	387.0	365.3	-4.7%

- Sales of products in Japan are shown in a gross sales basis.

3) Sales of products in Americas and EMEA

Unit: B¥

	FY16 Full Year	FY17 Full Year	Change	Change (%)	Unit: B¥ FY17 Revised Forecasts	Forecasts FY18 Full Year	Change from FY17 Change (%)
Tarceva	35.2	29.7	-5.6	-15.8%			
(US)	25.8	21.5	-4.3	-16.8%			
(ex-US)	9.4	8.2	-1.2	-13.0%			
Scan (Americas)	71.5	73.6	2.1	2.9%	72.6	69.4	-5.7%
AmBisome (Americas)	10.5	11.4	0.8	7.9%	11.1	11.5	1.2%
CRESEMBA (Americas)	5.8	9.6	3.8	66.4%	8.8	10.5	8.8%

4) Sales in Americas and EMEA (Local currency)

Unit: M$

Americas	FY16 Full Year	FY17 Full Year	Change	Change (%)	Unit:M$ FY17 Revised Forecasts	Forecasts FY18 Full Year	Change from FY17 Change (%)
Sales	3,805	3,909	104	2.7%	3,917	4,042	3.4%
XTANDI	1,286	1,404	118	9.2%	1,370	1,474	5.0%
US	1,215	1,303	88	7.2%	1,270	1,355	4.0%
Americas (ex-US)	71	102	30	42.4%	100	119	16.7%
Tarceva	325	268	-58	-17.7%			
US	238	194	-44	-18.7%			
ex-US	87	74	-13	-15.0%			
VESIcare	490	372	-118	-24.0%	411	377	1.2%
Myrbetriq	510	657	147	28.7%	658	806	22.8%
Prograf	252	232	-20	-8.0%	231	191	-17.4%
Scan	660	664	4	0.6%	657	661	-0.4%
MYCAMINE	113	111	-2	-1.4%	102	94	-15.1%
AmBisome	97	102	5	5.5%	100	109	6.8%
CRESEMBA	53	87	33	62.7%	80	100	14.9%

Unit: M€

EMEA	FY16 Full Year	FY17 Full Year	Change	Change (%)	Unit:M€ FY17 Revised Forecasts	Forecasts FY18 Full Year	Change from FY17 Change (%)
Sales	2,785	2,651	-134	-4.8%	2,651	2,645	-0.2%
XTANDI	718	823	105	14.6%	846	921	11.9%
Eligard	132	125	-7	-5.6%	139	126	1.4%
Vesicare	270	244	-26	-9.5%	242	229	-6.3%
BETMIGA	119	141	22	18.5%	143	169	20.1%
Omnic	138	138	0	0.2%	140	130	-5.8%
Sales by Astellas	118	121	3	2.5%	125	121	-0.2%
Bulk and Royalties	19	17	-3	-13.8%	15	9	-47.2%
Prograf	612	632	20	3.2%	626	598	-5.4%
Sales by Astellas	590	607	17	2.8%	602	584	-3.6%
Advagraf	252	272	20	8.0%			
Exports to third parties	22	25	3	14.8%	24	14	-46.3%
MYCAMINE	91	90	-1	-1.5%	86	70	-21.7%

- EMEA: Europe, Middle East and Africa

9.Consolidated statements of financial position

Unit: B¥

			31-Mar-17	31-Mar-18	
			Amount	Amount	Change
Assets			**1,814.1**	**1,858.2**	**44.1**
	Non-current assets		**937.4**	**1,012.6**	**75.2**
		Property, plant and equipment	191.1	181.3	-9.8
		Goodwill	168.5	213.0	44.5
		Other intangible assets	387.4	416.9	29.5
		Trade and other receivables	22.3	25.3	3.0
		Investments in associates and joint ventures	3.0	3.1	0.2
		Deferred tax assets	90.3	97.2	6.9
		Other financial assets	61.6	67.4	5.8
		Other non-current assets	13.2	8.4	-4.8
	Current assets		**876.7**	**845.6**	**-31.0**
		Inventories	182.5	147.6	-34.9
		Trade and other receivables	309.8	319.5	9.7
		Income tax receivable	11.0	8.4	-2.6
		Other financial assets	13.6	13.5	-0.0
		Other current assets	18.8	14.4	-4.4
		Cash and cash equivalents	340.9	331.7	-9.2
		Assets held for sale	-	10.4	10.4

Due to the adjustments of the provisional fair value for the acquisition of Ganymed Pharmaceuticals AG , consolidated statement of financial position as of 31 March, 2017 was retrospectively revised.

For the details, refer to Financial Results P.29

Unit: B¥

	31-Mar-17	31-Mar-18	
	Amount	Amount	Change
Equity and Liabilities	**1,814.1**	**1,858.2**	**44.1**
Equity	**1,271.8**	**1,268.3**	**-3.5**
Equity attributable to owners of the parent	**1,271.8**	**1,268.3**	**-3.5**
Share capital	103.0	103.0	-
Capital surplus	177.1	177.2	0.1
Treasury shares	-138.2	-136.0	2.3
Retained earnings	1,013.9	976.1	-37.8
Other components of equity	116.0	147.9	31.9
Liabilities	**542.3**	**589.9**	**47.7**
Non-current liabilities	**142.4**	**168.3**	**25.9**
Trade and other payables	0.4	3.5	3.1
Deferred tax liabilities	18.5	26.4	7.9
Retirement benefit liabilities	36.6	36.7	0.1
Provisions	4.9	4.9	-0.0
Other financial liabilities	28.4	49.4	21.0
Other non-current liabilities	53.5	47.4	-6.2
Current liabilities	**399.9**	**421.6**	**21.8**
Trade and other payables	182.8	140.9	-41.9
Income tax payable	10.9	25.2	14.3
Provisions	96.6	126.2	29.6
Other financial liabilities	3.0	7.6	4.6
Other current liabilities	106.5	121.7	15.2

10. Employees

Number of employees

	FY16 End	FY17 End
Total	17,202	16,617
Japan	7,029	6,825
Americas	3,016	2,840
EMEA	4,672	4,490
Asia and Oceania	2,485	2,462
Total Medical Representatives	5,750	5,330

- EMEA: Europe, Middle East and Africa

11. Shareholders

	FY16 End	FY17 End
Banks	30.7%	32.3%
Securities	3.5%	3.5%
Other companies	3.4%	3.2%
Foreign companies	49.3%	47.3%
Individuals and others	9.1%	9.3%
Treasury Stock*	4.1%	4.4%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust.

[For the year ended March 31,2018]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY17							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	322.6	-4.5%	317.2	1.0%	359.7	1.6%	300.9	-1.7%
Cost of sales	79.3	10.9%	69.5	-7.0%	90.1	-13.8%	55.3	-20.7%
Ratio to Sales	24.6%		21.9%		25.1%		18.4%	
Gross profit	243.3	-8.6%	247.6	3.5%	269.6	8.1%	245.5	3.9%
SG&A expenses	112.3	0.4%	116.0	6.4%	121.7	5.1%	128.3	-4.3%
Ratio to Sales	34.8%		36.6%		33.8%		42.6%	
Advertising and Sales Promotion	34.6	-3.5%	37.7	13.1%	39.4	9.7%	40.4	3.8%
Personnel expenses	43.6	0.3%	44.4	5.8%	44.2	-0.1%	46.2	-2.2%
Other	34.1	4.8%	33.8	0.7%	38.1	6.9%	41.7	-13.0%
R&D expenses	56.5	10.7%	51.0	4.8%	54.1	11.4%	59.2	-1.1%
Ratio to Sales	17.5%		16.1%		15.1%		19.7%	
Amortisation of intangible assets	9.0	-0.1%	9.0	2.8%	9.1	0.3%	8.8	-2.8%
Share of profits/losses of associates and joint ventures	-0.4	-	-0.5	-	-0.6	-	-1.0	-
Other income	9.7	-	0.3	106.6%	0.6	-91.0%	10.0	231.9%
Fair value remeasurements on contingent consideration	9.2	-	0.3	-	0.2	-	0.1	-
Gain from remeasurement relating to business combinations	-	-	-	-	-	-	5.9	-
Other expense	31.3	-	19.0	124.4%	1.0	-86.9%	24.7	299.6%
Impairment losses	26.0	-	10.8	41.5%	0.5	-87.5%	5.1	-17.3%
Restructuring costs	-0.1	-	3.3	334.5%	0.4	-82.4%	5.6	-
Net foreign exchange losses	5.1	-	3.5	-	-	-	2.1	-
Fair value remeasurements on contingent consideration	-	-	-	-	-	-	9.8	-
Operating profit	43.5	-53.1%	52.5	-18.1%	83.7	12.7%	33.5	13.4%
Ratio to Sales	13.5%		16.6%		23.3%		11.1%	
Finance income	5.2	328.9%	0.4	-65.1%	0.4	-96.4%	0.6	-93.4%
Gain on sales of available-for-sale financial assets	4.7	628.1%	0.0	-99.8%	-	-	-	-
Finance expense	0.3	-68.8%	0.2	-73.7%	0.7	-384.4%	0.6	6.2%
Impairment losses for available-for-sale financial assets	0.0	-99.5%	0.0	-85.0%	0.5	-	-	-
Profit before tax	48.5	-48.0%	52.8	-18.3%	83.4	-3.2%	33.5	-11.5%
Ratio to Sales	15.0%		16.6%		23.2%		11.1%	
Income tax expense	6.0	-77.4%	13.1	-18.8%	22.9	2.2%	11.4	-663.8%
Profit for the year	42.5	-36.2%	39.6	-18.2%	60.5	-5.1%	22.1	-44.7%
Ratio to Sales	13.2%		12.5%		16.8%		7.3%	
Comprehensive income	83.5	-	80.6	119.9%	72.9	-56.6%	-38.6	-

2. Consolidated Results (Core Basis)

Unit: B¥

	FY17							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	322.6	-4.5%	317.2	1.0%	359.7	1.6%	300.9	-1.7%
Cost of sales	79.3	10.9%	69.5	-7.0%	90.1	-13.8%	55.3	-20.7%
Ratio to Sales	24.6%		21.9%		25.1%		18.4%	
Gross profit	243.3	-8.6%	247.6	3.5%	269.6	8.1%	245.5	3.9%
SG&A expenses	112.3	0.4%	116.0	6.4%	121.7	5.1%	128.3	-4.3%
Ratio to Sales	34.8%		36.6%		33.8%		42.6%	
Advertising and Sales Promotion	34.6	-3.5%	37.7	13.1%	39.4	9.7%	40.4	3.8%
Personnel expenses	43.6	0.3%	44.4	5.8%	44.2	-0.1%	46.2	-2.2%
Other	34.1	4.8%	33.8	0.7%	38.1	6.9%	41.7	-13.0%
R&D expenses	56.5	10.7%	51.0	4.8%	54.1	11.4%	59.2	-1.1%
Ratio to Sales	17.5%		16.1%		15.1%		19.7%	
Amortisation of intangible assets	9.0	-0.1%	9.0	2.8%	9.1	0.3%	8.8	-2.8%
Share of profits/losses of associates and joint ventures	-0.4	-	-0.5	-	-0.6	-	-1.0	-
Operating profit	65.1	-30.7%	71.2	-1.8%	84.1	11.6%	48.2	47.4%
Ratio to Sales	20.2%		22.5%		23.4%		16.0%	
Finance income	0.5	-15.2%	0.4	69.4%	0.4	-18.0%	0.6	75.4%
Finance expense	0.2	-59.0%	0.2	-71.9%	0.2	-190.6%	0.5	81.5%
Profit before Tax	65.4	-30.4%	71.4	-0.9%	84.3	10.6%	48.3	47.4%
Ratio to Sales	20.3%		22.5%		23.4%		16.1%	
Income tax expense	13.4	-49.8%	16.7	-10.3%	23.0	17.8%	11.9	-451.8%
Profit for the year	51.9	-22.7%	54.7	2.4%	61.2	8.2%	36.4	0.8%
Ratio to Sales	16.1%		17.3%		17.0%		12.1%	

3. Sales by Region

Unit: B¥

			FY17							
			APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales			322.6	-4.5%	317.2	1.0%	359.7	1.6%	300.9	-1.7%
	Japan		114.2	-8.1%	98.8	-12.5%	124.3	-13.0%	83.9	-16.7%
		Ratio to Sales	35.4%		31.1%		34.6%		27.9%	
	Americas		101.6	-5.6%	106.8	7.8%	118.5	16.8%	106.5	2.1%
		Ratio to Sales	31.5%		33.7%		32.9%		35.4%	
	EMEA		83.4	-2.3%	85.7	6.1%	91.0	4.7%	83.7	7.5%
		Ratio to Sales	25.9%		27.0%		25.3%		27.8%	
	Asia and Oceania		23.4	13.2%	25.9	22.9%	25.9	14.3%	26.7	15.2%
		Ratio to Sales	7.3%		8.2%		7.2%		8.9%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

4. Addition to Property,Plant and Equipment Depreciation/Amortisation

Unit: B¥

		FY17							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Addition to Property, Plant and Equipment									
	Consolidated	5.8	48.4%	4.6	-8.1%	6.7	44.0%	7.0	-32.1%
Depreciation (PP&E)									
	Consolidated	5.4	-3.0%	5.6	3.5%	5.4	-0.7%	5.8	3.3%
Amortisation (Intangible Assets) *									
	Consolidated	10.6	1.8%	10.7	5.0%	10.8	1.8%	10.7	0.2%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

5. Sales of major products

1) Sales of global products

Unit: B¥

	FY17							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI	67.9	5.8%	72.4	17.2%	79.6	25.8%	74.4	18.4%
US	33.4	-6.5%	34.9	7.1%	39.9	24.2%	36.2	15.8%
ex-US	34.5	21.1%	37.5	28.5%	39.8	27.5%	38.2	20.9%
Japan	6.5	7.0%	6.4	11.6%	7.2	15.3%	6.0	11.6%
Americas (ex-US)	2.5	40.0%	2.8	59.4%	3.3	99.7%	2.6	4.5%
EMEA	24.4	22.1%	26.9	29.3%	27.8	24.2%	27.7	24.9%
Asia and Oceania	1.2	62.9%	1.4	60.4%	1.5	61.6%	1.8	23.2%
Eligard	4.4	-0.6%	4.0	16.2%	4.3	3.0%	3.8	-1.3%
EMEA	4.3	-1.1%	3.9	15.8%	4.2	2.1%	3.7	-2.5%
Asia and Oceania	0.1	39.7%	0.1	35.1%	0.1	71.3%	0.1	86.7%
Vesicare	24.6	-19.2%	25.1	-14.4%	28.8	-2.3%	23.8	-11.2%
Japan	6.4	-8.0%	5.7	-4.7%	6.7	-4.1%	5.0	-10.7%
Americas	9.3	-31.4%	10.4	-26.1%	12.3	-4.4%	9.2	-26.5%
EMEA	7.5	-13.8%	7.5	-4.3%	8.2	1.0%	8.4	14.4%
Asia and Oceania	1.3	9.7%	1.2	5.7%	1.3	-4.5%	1.2	-7.7%
Betanis/Myrbetriq/BETMIGA	27.2	15.6%	30.4	37.1%	35.5	36.9%	32.6	20.0%
Japan	7.2	12.3%	6.9	16.8%	8.4	15.8%	7.0	9.8%
Americas	15.0	15.9%	17.8	46.7%	20.8	49.4%	19.2	17.8%
EMEA	3.9	12.1%	4.4	29.6%	5.0	32.4%	5.0	43.3%
Asia and Oceania	1.1	60.3%	1.3	74.3%	1.4	33.0%	1.5	36.1%
Harnal/Omnic	12.1	-0.3%	13.3	17.0%	12.7	4.4%	11.5	-3.9%
Sales by Astellas	11.8	2.3%	12.3	12.5%	12.3	4.0%	11.1	0.0%
Japan	2.1	-18.6%	1.9	-15.3%	2.0	-17.3%	1.4	-26.3%
EMEA	3.8	5.1%	4.0	27.5%	4.0	8.0%	3.9	9.3%
Asia and Oceania	5.7	9.6%	6.1	15.0%	5.9	10.1%	5.6	5.8%
Bulk and Royalties	0.3	-49.2%	0.9	152.1%	0.4	19.4%	0.5	-49.1%
Prograf	49.4	0.0%	49.8	11.3%	50.9	5.9%	48.3	10.0%
Sales by Astellas	48.1	-1.2%	49.0	11.5%	50.4	5.8%	47.7	10.2%
Japan (Including Graceptor)	12.7	-1.5%	12.3	3.5%	13.3	0.4%	9.9	-7.8%
Americas	6.2	-18.8%	6.2	-3.5%	6.4	-2.2%	6.8	2.9%
EMEA	19.6	3.1%	19.8	19.5%	20.1	12.7%	19.1	15.0%
Advagraf	8.6	9.3%	9.1	27.4%	9.3	22.3%	8.3	13.3%
Asia and Oceania	9.5	5.0%	10.6	18.1%	10.6	6.0%	11.9	27.4%
Exports to third parties	1.4	81.1%	0.9	1.2%	0.5	13.3%	0.6	-1.8%
Funguard/MYCAMINE	10.3	2.1%	10.6	5.4%	10.7	0.7%	9.4	-0.9%
Japan	2.7	-0.5%	2.8	-3.3%	3.0	-7.9%	2.0	-11.8%
Americas	3.0	-3.0%	2.9	0.9%	3.4	8.8%	3.1	-3.2%
EMEA	2.9	5.5%	3.2	13.6%	2.8	0.2%	2.7	11.6%
Asia and Oceania	1.6	11.5%	1.7	15.6%	1.5	4.3%	1.6	0.0%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

	FY17							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	6.5	7.0%	6.4	11.6%	7.2	15.3%	6.0	11.6%
Vesicare	6.4	-8.0%	5.7	-4.7%	6.7	-4.1%	5.0	-10.7%
Betanis	7.2	12.3%	6.9	16.8%	8.4	15.8%	7.0	9.8%
Harnal	2.1	-18.6%	1.9	-15.3%	2.0	-17.3%	1.4	-26.3%
Prograf （Including Graceptor ）	12.7	-1.5%	12.3	3.5%	13.3	0.4%	9.9	-7.8%
Funguard	2.7	-0.5%	2.8	-3.3%	3.0	-7.9%	2.0	-11.8%
<Local products in Japan>								
Micardis [Family]	23.1	-6.2%	8.3	-62.4%	8.9	-66.5%	5.9	-70.0%
Micombi	2.4	-7.5%	0.9	-59.0%	1.0	-62.3%	0.6	-67.7%
Micamlo	6.7	-2.2%	2.5	-59.2%	2.7	-63.8%	1.9	-67.8%
Celecox	12.4	0.3%	12.3	4.9%	13.2	2.0%	10.4	-0.9%
Symbicort	10.2	4.1%	8.8	-0.7%	11.9	0.2%	8.5	-1.5%
Bonoteo	3.5	-4.6%	3.3	-1.7%	3.7	-3.1%	2.8	-5.2%
Geninax	2.3	-4.8%	1.7	-5.1%	3.1	-15.5%	2.1	-7.9%
Vaccines	3.4	-11.1%	3.4	-53.1%	19.5	-4.8%	3.1	4.9%
Argamate	1.5	-2.4%	1.4	0.1%	1.6	1.8%	1.2	-4.0%
Gonax	1.2	6.5%	1.2	8.2%	1.3	7.4%	1.1	-6.5%
Cimzia	2.2	14.1%	2.3	18.2%	2.5	19.0%	2.0	12.8%
Suglat	2.9	22.3%	2.9	30.4%	3.8	43.3%	2.0	-10.1%
Repatha	0.3		0.4		0.5		0.5	
Linzess	0.1		0.3		0.4		0.5	
Lipitor	5.4	-15.5%	5.0	-12.4%	5.4	-14.8%	3.8	-19.5%
Myslee	3.5	-11.4%	3.4	-7.2%	3.6	-8.5%	2.8	-11.0%
Seroquel	1.8	-19.9%	1.6	-15.4%	1.7	-14.2%	1.1	-21.8%
Total Rx Sales In Japanese market	106.1	-7.5%	88.0	-17.7%	114.8	-15.8%	74.4	-21.3%

- Sales of products in Japan are shown in a gross sales basis.

3) Sales of products in Americas and EMEA

Unit: B¥

	FY17							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Tarceva	8.3	-11.6%	8.5	0.2%	7.8	-20.4%	5.0	-33.2%
(US)	6.2	-9.1%	6.5	1.7%	5.7	-20.5%	3.1	-43.6%
(ex-US)	2.2	-18.0%	2.0	-4.5%	2.1	-20.3%	2.0	-6.3%
Scan (Americas)	18.7	-3.0%	17.9	11.0%	18.3	11.5%	18.7	-5.2%
AmBisome (Americas)	2.9	18.5%	2.8	22.0%	3.1	2.1%	2.5	-7.2%
CRESEMBA (Americas)	2.1	64.0%	2.1	72.8%	2.7	66.9%	2.7	63.1%

- EMEA: Europe, Middle East and Africa

4) Sales in Americas and EMEA (Local currency)

Unit:M$

	FY17							
Americas	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	914	-8.1%	962	-0.7%	1,050	13.3%	983	7.3%
XTANDI	323	-6.8%	340	1.2%	383	24.3%	359	21.2%
US	301	-8.9%	314	-1.3%	353	20.6%	334	22.3%
Americas (ex-US)	22	36.3%	25	47.2%	30	94.1%	24	8.4%
Tarceva	75	-13.9%	77	-7.7%	69	-23.2%	47	-27.9%
US	55	-11.5%	59	-6.2%	51	-23.3%	29	-38.5%
ex-US	20	-20.2%	18	-12.3%	18	-23.0%	18	-0.5%
VESIcare	84	-33.2%	94	-31.7%	110	-7.0%	85	-22.1%
Myrbetriq	135	12.8%	160	35.3%	185	44.6%	177	22.5%
Prograf	56	-20.9%	56	-11.3%	57	-5.1%	63	8.3%
Scan	168	-5.6%	161	2.1%	162	8.2%	172	-1.0%
MYCAMINE	27	-5.6%	26	-7.0%	30	5.4%	28	1.6%
AmBisome	26	15.3%	25	12.6%	28	-1.6%	23	-2.3%
CRESEMBA	19	59.7%	19	59.5%	24	61.0%	25	69.4%

Unit:M€

	FY17							
EMEA	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	683	-2.4%	656	-7.1%	684	-7.2%	627	-2.2%
XTANDI	200	22.0%	206	13.8%	209	10.1%	208	13.5%
Eligard	35	-1.2%	30	0.2%	32	-9.7%	28	-11.7%
Vesicare	61	-13.9%	58	-16.3%	62	-10.4%	63	4.5%
BETMIGA	32	11.9%	33	13.8%	38	17.8%	37	30.6%
Omnic	34	-2.7%	38	23.1%	33	-3.7%	33	-12.2%
Sales by Astellas	31	4.9%	31	11.3%	30	-4.5%	29	-0.7%
Bulk and Royalties	2	-49.3%	7	121.9%	3	4.0%	4	-54.4%
Prograf	172	5.9%	158	3.4%	154	-0.5%	147	4.0%
Sales by Astellas	161	2.9%	152	4.3%	151	-0.3%	143	4.6%
Advagraf	71	9.2%	69	11.4%	70	8.3%	62	2.8%
Exports to third parties	11	81.2%	7	-12.7%	3	-5.2%	4	-12.2%
MYCAMINE	24	5.4%	24	-0.1%	21	-11.8%	20	1.4%

- EMEA: Europe, Middle East and Africa

R&D Pipeline (As of Apr 2018)

Underlined items indicate changes from the previous announcement on Jan 31, 2018.

Oncology (1/2)

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Castration-resistant prostate cancer (Tablet)	Approved (Feb. 2018) / Japan	Oral	Pfizer	New formulation
		Non-metastatic castration-resistant prostate cancer	Filed (Jan. 2018) / US, Europe			New indication
		Prostate cancer in patients with non-metastatic biochemical recurrence	P-III / US, Europe, Asia			New indication
		Metastatic hormone-sensitive prostate cancer	P-III / US, Europe, Japan, Asia			New indication
ASP3550 degarelix	GnRH antagonist	Prostate cancer (3-month formulation)	Filed (Nov. 2017) / Japan	Injection	Ferring	New formulation
AMG 103 blinatumomab	Anti-CD19 BiTE antibody	Acute lymphoblastic leukemia	Filed (Jan. 2018) / Japan	Injection	Amgen (co-development with Amgen Astellas)	
ASP2215 gilteritinib	FLT3/AXL inhibitor	Relapsed or refractory acute myeloid leukemia	Filed (Mar. 2018) / US, Japan P-III / US, Europe, Japan, Asia	Oral	In-house	
		Post-chemo maintenance acute myeloid leukemia	P-III / US, Europe, Japan, Asia			
		Post-HSCT maintenance acute myeloid leukemia	P-III / US, Europe, Japan, Asia			
		Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II/III / US, Europe, Japan, Asia			
		Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-I / US, Japan			
IMAB362 zolbetuximab	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III / US, Europe, Japan, Asia	Injection	In-house (Ganymed)	
AGS-16C3F	ADC targeting ENPP3	Renal cell carcinoma	P-II / US, Europe	Injection	In-house (ADC technology in-licensed from Seattle Genetics)	
ASG-22ME enfortumab vedotin	ADC targeting nectin-4	Urothelial cancer	P-II / US, Europe, Japan, Asia P-I / Japan	Injection	In-house (co-development with Seattle Genetics)	
AGS67E		Lymphoid malignancies	P-I	Injection	In-house (ADC technology in-licensed from Seattle Genetics)	

Oncology (2/2)

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
AGS62P1		Acute myeloid leukemia	P-I	Injection	In-house (ADC technology, EuCODE license from Ambrx)	
ASP8374/PTZ-201		Cancer	P-I	Injection	Option agreement with Potenza Therapeutics	

Updates from the previous announcement (Jan. 2018):
MDV3100 (enzalutamide): Approval of the tablet formulation for CRPC obtained in Japan in Feb 2018.
ASP2215 (gilteritinib): Applications of market approval for FLT 3 mutation-positive relapsed or refractory acute myeloid leukemia were submitted in Japan and US in Mar 2018.

Urology and Nephrology

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity in pediatric patients	Approved (Feb. 2018) / Europe Filed (Feb. 2017) / US	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Combination therapy of solifenacin and mirabegron	Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency	Filed (Jun. 2017) / US	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	P-III / Europe P-III / Japan	Oral	FibroGen	
YM178 mirabegron	Beta 3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients	P-III / Europe	Oral	In-house	New indication (pediatric)
YM311 (FG-2216)	HIF stabilizer	Renal anemia	P-II / Europe P-I / Japan	Oral	FibroGen	
ASP8232	VAP-1 inhibitor	Diabetic kidney disease	P-II / Europe	Oral	In-house	
ASP6294	Nerve Growth Factor (NGF) neutralization antibody	Bladder pain syndrome / Interstitial cystitis	P-II / Europe	Injection	In-house	
ASP8302	Muscarine M_3 receptor positive allosteric modulator	Underactive bladder	P-II / Europe, Japan	Oral	In-house	
ASP7713		Underactive bladder	P-I	Oral	In-house	
MA-0217		Acute kidney injury	P-I	Injection	In-house (Mitobridge)	

Update from the previous announcement (Jan. 2018):
YM905 (solifenacin): Approval for neurogenic detrusor overactivity in pediatric patients obtained in EU in Feb 2018.

Immunology and Neuroscience

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
FK506 tacrolimus	Immunosuppressant	Prevention of rejection after organ transplantation (Granule formulation in pediatric use)	Filed (Jul. 2017) / US	Oral	In-house	New formulation
ASP015K peficitinib	JAK inhibitor	Rheumatoid arthritis	P-III / Japan, Asia P-II / US, Europe	Oral	In-house	
ASKP1240 bleselumab	Anti-CD40 monoclonal antibody	Recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients	P-II / US	Injection	Kyowa Hakko Kirin	
ASP8062	$GABA_B$ receptor positive allosteric modulator	Fibromyalgia	P-II / US	Oral	In-house	
ASP0819	$Calcium^{2+}$-activated K^+ channel opener	Fibromyalgia	P-II / US	Oral	In-house	
ASP4070 (JRC2-LAMP-vax)	DNA vaccine for Japanese red cedar	Pollinosis caused by Japanese red cedar	P-II / Japan	Injection	Immunomic Therapeutics	
ASP5094	Anti-alpha-9 integrin monoclonal antibody	Rheumatoid arthritis	P-II / Japan	Injection	In-house	
ASP4345	Dopamine D_1 receptor positive allosteric modulator	Cognitive impairment associated with schizophrenia	P-II / US	Oral	In-house	
ASP0892		Peanut allergy	P-I	Injection	Immunomic Therapeutics	
ASP1807 (CC8464)		Neuropathic pain	P-I	Oral	Chromocell	
ASP6981		Cognitive impairment associated with schizophrenia	P-I	Oral	In-house	

Update from the previous announcement (Jan. 2018):
ASP1707: Discontinued phase 2 program for rheumatoid arthritis because phase 2 study did not meet its primary endpoint.

Others

*Compounds with "In-house" in this column include ones discovered by collaborative research.

Code No. Generic Name	Classification	Target Disease	Phase / Area	Dosage Form	Licensor*	Remarks
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis for those at high risk of fracture	Filed (Dec. 2016) / Japan	Injection	Amgen (co-development with Amgen Astellas)	
ipragliflozin/ sitagliptin	Fixed dose combination of ipragliflozin and sitagliptin	Type 2 diabetes	Approved (Mar 2018) / Japan	Oral	In-house (co-development with MSD and Kotobuki)	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes	Filed (Jan. 2018) / Japan	Oral	In-house (co-development with Kotobuki)	New indication
ASP0456 linaclotide	Guanylate cyclase-C receptor agonist	Chronic constipation	Filed (Sep. 2017) / Japan	Oral	Ironwood	New indication
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Filed (Jul. 2017) / Japan	Oral	Merck	
		Clostridium difficile infection in pediatric patients	P-III / Europe			New indication (pediatric)
ESN364 fezolinetant	NK3 receptor antagonist	Menopause-related vasomotor symptoms	P-II / US	Oral	In-house (Ogeda)	
CK-2127107 reldesemtiv	Fast skeletal troponin activator	Spinal muscular atrophy	P-II / US	Oral	Cytokinetics	
		Chronic obstructive pulmonary disease	P-II / US			
		Amyotrophic lateral sclerosis	P-II / US			
ASP7317	Cell therapy (Retinal pigment epithelium cell)	Dry age-related macular degeneration, Stargardt's macular degeneration	P-II / US	Injection	In-house (Astellas Institute for Regenerative Medicine)	
MA-0211		Duchenne muscular dystrophy	P-I	Oral	In-house (Mitobridge)	

Updates from the previous announcement (Jan. 2018):
ipragliflozin/sitagliptin: Approval for the fixed dose combination of ipragliflozin and sitagliptin for Type 2 diabetes obtained in Japan in Mar 2018.
ASP0113: Discontinued the phase 3 program for cytomegalovirus reactivation in hematopoietic cell transplant recipients because phase 3 study did not meet its primary endpoint.
ASP1707: Discontinued the phase 2 program for endometriosis due to the comprehensive consideration including strategic prioritization.